Rongzhi (蓉芷)
Ce contenu n’est pas encore disponible dans votre langue.
Rongzhi (蓉芷) is the brand associated with a Chinese deoxycholic-acid injection approved in 2025 for improvement of moderate to severe contour protrusion or excessive fullness caused by submental fat in adults. The approval belongs to a specific finished drug: a 2 mL vial containing 20 mg deoxycholic acid, with Nanjing Minova Pharmaceutical Technology as marketing-authorization holder and Guangdong Xinghao Pharmaceutical as the finished-product manufacturer in available registration-derived records.
Quick reference
Section titled “Quick reference”| Field | Rongzhi / 蓉芷 |
|---|---|
| Generic name | Deoxycholic Acid Injection (去氧胆酸注射液) |
| Strength | 2 mL:20 mg, equivalent to 10 mg/mL |
| Dosage form | Injection |
| China approval date | June 10, 2025 |
| NMPA approval number | 国药准字H20254519 |
| Approved objective | Improvement of moderate to severe contour protrusion or excessive fullness caused by submental-fat accumulation in adults |
| Marketing-authorization holder | Nanjing Minova Pharmaceutical Technology Co., Ltd. (南京迈诺威医药科技有限公司) |
| Finished-product manufacturer | Guangdong Xinghao Pharmaceutical Co., Ltd. (广东星昊药业有限公司) |
The approval number, date, generic name, strength, holder, and manufacturing company are reproduced in registration-derived drug records (approval-record reproduction 🔗; NMPA approval-detail reproduction 🔗). An official announcement from Hefei Lifeon Pharmaceutical, an investor in Minova, independently confirms the approval number, date context, brand, developer, and indication (Lifeon company announcement 🔗).
Approval identity and verification boundary
Section titled “Approval identity and verification boundary”The critical identifier is 国药准字H20254519, not the brand name alone. Available records associate that number with:
| Regulatory field | Recorded value |
|---|---|
| Generic product name | 去氧胆酸注射液 |
| English generic name | Deoxycholic Acid Injection |
| Product category | Chemical drug |
| Strength | 2 mL:20 mg |
| Approval date | June 10, 2025 |
| Marketing-authorization holder | 南京迈诺威医药科技有限公司 |
| Manufacturing site/company | 广东星昊药业有限公司, Zhongshan, Guangdong |
China’s NMPA domestic-drug database is the controlling source for the authorization. Its public search interface does not currently expose a stable, directly linkable product-detail page for this record in the reviewed web environment (NMPA domestic-drug search 🔗). The role fields above are therefore cross-checked against reproductions of the NMPA record and an official company announcement, but should be rechecked in the live NMPA database when making a regulatory or procurement decision.
This limitation does not justify replacing the approval number with vague wording such as “NMPA certified.” Approval applies to the named finished drug, holder, manufacturer, strength, and indication.
Brand, generic drug, and company are different entities
Section titled “Brand, generic drug, and company are different entities”Rongzhi is the brand-facing identity. Deoxycholic Acid Injection is the approved generic product name. Nanjing Minova is the marketing-authorization holder and company described as the developer; Guangdong Xinghao is the finished-product manufacturer identified in registration-derived records.
| Role | Supported relationship |
|---|---|
| Brand | Rongzhi / 蓉芷 |
| Product developer | Nanjing Minova describes the product as independently developed; Lifeon repeats that relationship in its official announcement |
| Marketing-authorization holder | Nanjing Minova Pharmaceutical Technology Co., Ltd. |
| Finished-product manufacturer | Guangdong Xinghao Pharmaceutical Co., Ltd. |
| Investor relationship | Hefei Lifeon Pharmaceutical describes Minova as an invested company, not as the product manufacturer or approval holder |
These roles should not be compressed into “made by Minova” or “a Lifeon product.” Nor should the manufacturing company be assumed to own the brand.
Formulation boundary
Section titled “Formulation boundary”The public approval record establishes deoxycholic acid, a strength of 2 mL:20 mg, and an injectable dosage form. A complete official package insert or regulator-hosted excipient list was not located in the reviewed public sources.
Accordingly, this page does not infer:
- an excipient system from Kybella, Belkyra, or V-OLET
- pH, preservative, or buffer composition
- vial count per commercial pack
- storage conditions
- interchangeability with another 10 mg/mL DCA product
Shared active ingredient and concentration are important comparison fields, but they do not prove identical formulation, impurity profile, manufacture, clinical evidence, or instructions.
Approved use remains submental
Section titled “Approved use remains submental”The company announcement describes the approved use as improvement of moderate to severe contour protrusion or excessive fullness caused by submental-fat accumulation in adults (Lifeon announcement 🔗). This is an adult submental indication.
It should not be expanded into approval for:
- generalized facial slimming
- jowls outside the labeled area
- abdomen, arms, thighs, or back
- obesity treatment or body-weight reduction
- any local-fat deposit regardless of cause
Company phrases such as “precise local fat reduction” are commercial framing, not additional approved anatomy.
Evidence boundary
Section titled “Evidence boundary”Minova and company-linked reports describe a development program and phase 3 evaluation, but a peer-reviewed pivotal publication and a complete public NMPA review report were not located for this initial profile. Claims about response rate, skin tightening, duration, superiority, or ethnic tailoring should remain unconfirmed unless supported by accessible product-specific evidence.
The 2025 approval establishes that NMPA authorized the finished drug for the stated indication. It does not by itself establish:
- clinical equivalence to Kybella, Belkyra, or V-OLET
- superiority over surgery or energy-based treatment
- efficacy outside the submental region
- a class-wide safety advantage over other DCA products
- that every marketed vial bearing the Rongzhi name is authentic
Future evidence updates should record the exact formulation, trial registry or protocol, participant population, comparator, endpoints, treatment exposure, follow-up, and adverse events.
Safety and clinical-use limits
Section titled “Safety and clinical-use limits”Deoxycholic acid is cytolytic rather than tissue-selective after incorrect placement. Product-specific labeling is therefore essential for contraindications, anatomy warnings, adverse reactions, storage, and administration. Until the complete current Chinese package insert is available through a stable primary source, safety statements from another DCA brand should not be presented as Rongzhi labeling.
Clinically relevant categories to verify in the controlling insert include:
- treatment-site infection
- marginal mandibular nerve injury
- dysphagia
- bleeding and hematoma
- injury to vessels, glands, lymph nodes, or muscle
- ulceration, necrosis, and infection
- expected local swelling, pain, numbness, and induration
This page intentionally does not provide an injection grid, per-site volume, session maximum, or interval. Those are product-label and training matters, not ingredient-level rules.
Related reference
Section titled “Related reference”- Fat-Reduction Injectables places Rongzhi within the regional authorization and finished-formulation graph.